Selinexor

WHO Grade 3 Glioma

Children's Oncology GroupSmall moleculePhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

23 Active assets in the WHO Grade 3 Glioma cohort.

Asset / Sponsor	Phase	Rating
Sorafenib Virginia Commonwealth University	Phase 2	BB
Everolimus Nationwide Children's Hospital	Phase 2	B
Fycompa Mayo Clinic	Phase 4	B
Lomustine M.D. Anderson Cancer Center	Phase 2	B
THIOGUANINE ANHYDROUS M.D. Anderson Cancer Center	Phase 2	B

View all 38 →

Same molecule, other indications

Selinexor is also rated in:

diffuse large B-cell lymphomaDormant

BBB

Indicative ·

72 / 100

mantle cell lymphomaDormant

BB

Indicative ·

70 / 100

relapsed/refractory diffuse large B-cell lymphomaDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.